(90) Yttrium ((90) Y)-Ibritumomab-Tiuxetan combines the targeting advantage of a monoclonal antibody with the radiosensitivity of Follicular Lymphoma (FL). Previous studies showed that 90Y-IT is safe and effective in relapsed/refractory indolent FL, irrespective of prior treatment with rituximab. This multicentre trial aimed to evaluate the safety and the efficacy of "upfront" single-agent ((90) Y)-Ibritumomab-Tiuxetan in advanced-stage FL. The primary objective was the incidence of responses in terms of complete (CR) and partial remission (PR). Fifty patients with stage II "bulky", III or IV FL received a single treatment course with ((90) Y)-Ibritumomab-Tiuxetan as initial therapy. The median age was 60 years. Bone marrow involvement (<25\%) was observed in 24 patients (48\%) and 7 (14\%) had an elevated lactate dehydrogenase level. The overall response (ORR) and CR rates were 94\% and 86\%, respectively with a median follow-up of 38·8 months. The median progression-free survival (PFS) was not reached, whereas the 3-year estimated PFS and overall survival (OS) rate was 63·4\% and 90\%, respectively. Grade 3/4 neutropenia and thrombocytopenia occurred in 30\% and 26\% of patients respectively; none experienced grade 3/4 non-haematological toxicity. No cases of secondary haematological malignancies were observed. ((90) Y)-Ibritumomab-Tiuxetan was demonstrated to be highly effective and safe as first-line treatment for advanced-stage FL.

Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study / A. Ibatici;G. M. Pica;S. Nati;U. Vitolo;B. Botto;C. Ciochetto;M. Petrini;S. Galimberti;E. Ciabatti;E. Orciuolo;P. L. Zinzani;N. Cascavilla;F. Guolo;G. F. Orcioni;A. M. Carella. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - STAMPA. - 164:(2014), pp. 710-716. [10.1111/bjh.12695]

Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.

ZINZANI, PIER LUIGI;
2014

Abstract

(90) Yttrium ((90) Y)-Ibritumomab-Tiuxetan combines the targeting advantage of a monoclonal antibody with the radiosensitivity of Follicular Lymphoma (FL). Previous studies showed that 90Y-IT is safe and effective in relapsed/refractory indolent FL, irrespective of prior treatment with rituximab. This multicentre trial aimed to evaluate the safety and the efficacy of "upfront" single-agent ((90) Y)-Ibritumomab-Tiuxetan in advanced-stage FL. The primary objective was the incidence of responses in terms of complete (CR) and partial remission (PR). Fifty patients with stage II "bulky", III or IV FL received a single treatment course with ((90) Y)-Ibritumomab-Tiuxetan as initial therapy. The median age was 60 years. Bone marrow involvement (<25\%) was observed in 24 patients (48\%) and 7 (14\%) had an elevated lactate dehydrogenase level. The overall response (ORR) and CR rates were 94\% and 86\%, respectively with a median follow-up of 38·8 months. The median progression-free survival (PFS) was not reached, whereas the 3-year estimated PFS and overall survival (OS) rate was 63·4\% and 90\%, respectively. Grade 3/4 neutropenia and thrombocytopenia occurred in 30\% and 26\% of patients respectively; none experienced grade 3/4 non-haematological toxicity. No cases of secondary haematological malignancies were observed. ((90) Y)-Ibritumomab-Tiuxetan was demonstrated to be highly effective and safe as first-line treatment for advanced-stage FL.
2014
Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study / A. Ibatici;G. M. Pica;S. Nati;U. Vitolo;B. Botto;C. Ciochetto;M. Petrini;S. Galimberti;E. Ciabatti;E. Orciuolo;P. L. Zinzani;N. Cascavilla;F. Guolo;G. F. Orcioni;A. M. Carella. - In: BRITISH JOURNAL OF HAEMATOLOGY. - ISSN 0007-1048. - STAMPA. - 164:(2014), pp. 710-716. [10.1111/bjh.12695]
A. Ibatici;G. M. Pica;S. Nati;U. Vitolo;B. Botto;C. Ciochetto;M. Petrini;S. Galimberti;E. Ciabatti;E. Orciuolo;P. L. Zinzani;N. Cascavilla;F. Guolo;G. F. Orcioni;A. M. Carella
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/506407
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 28
  • ???jsp.display-item.citation.isi??? 29
social impact